41 results about "Clotting factor" patented technology

The invention provides double-stranded ribonucleic acid for reducing blood coagulation factor XI expression and a modifier and application of the double-stranded ribonucleic acid. Cell experiment results show that the oligonucleotide duplex can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The invention relates to oil seal liquid and application thereof in blood coagulation detection, and belongs to the technical field of blood coagulation detection. The oil seal liquid can form a uniform film when covering a plasma sample, the activity of thrombin is not affected while air is isolated, and in addition, the oil seal liquid is a biological inert formula, is easy to clean and does not generate adsorption or reaction with blood coagulation factors and reagents. Therefore, the oil seal liquid and the sample are incubated synchronously in the pre-warming stage, and errors caused by sample evaporation and temperature fluctuation in the pre-warming stage can be reduced. Compared with traditional paraffin oil, the oil seal liquid can effectively isolate air to avoid sample evaporation and reduce reagent interference, is easy to clean, provides reliable technical support for blood coagulation factor deficiency and precise identification of inhibitors, and is suitable for APTT correction experiments, PT correction experiments or clinical detection and application of lupus anticoagulant (LA).

The present invention relates to the technical field of biology, and in particular to a nucleic acid targeting coagulation factor XI and a use thereof. The nucleic acid of the present invention can effectively reduce the level of coagulation factor XI and can effectively inhibit the formation of thrombi, thereby preventing and / or treating multiple diseases caused by thrombi, such as pulmonary embolism, venous embolism, deep venous embolism, myocardial infarction, and stroke.

The present disclosure describes cyclic peptide inhibitors of Factor XI (FXI), preferably FXIa. Also described are pharmaceutical compositions comprising the cyclic peptides and their use in treating conditions, diseases and / or disorders responsive to FXI, preferably FXIa inhibition, including thrombosis or thrombo-inflammatory conditions.

The application discloses a cold deposit full-automatic post-processing instrument and a preparation method of cold deposit blood clotting factors. The cold deposit full-automatic post-processing instrument comprises a separation system, the separation system comprises a squeezing disc and a weighing disc, and the squeezing disc is provided with a squeezing cavity; a transportation tensioning system can transport the first blood bag to the squeezing cavity, transport the second blood bag to the weighing disc, cut the pipeline of the double-pipe and tighten the double-pipe; a heat sealing system can heat seal the first heat sealing point, the second heat sealing point, the third heat sealing point and the fourth heat sealing point on the tightened double-pipe; a material head removing system, the transportation tensioning system can transport the double blood bag after heat sealing to the material head removing system to remove the Y-shaped material head; and a collection system comprising a first collection box and a second collection box. The application can improve the heat sealing efficiency of the blood bag, improve the working environment and shorten the exposure time of the plasma at room temperature.

The present invention relates to a method and apparatus for determining the activity of clotting factors in diluted capillary whole blood, citrated whole blood and citrated plasma. The invention also includes the detection of hemoglobin content in the whole blood sample to correct for clotting time so that the clotting time values are not affected by hemoglobin and hematocrit.

The invention discloses a compound with high inhibitory activity on blood coagulation factor XIIa as well as a pharmaceutical composition and application of the compound. The structural formula of the compound is shown as a general formula (I) or (II). The benzo-seven-membered ring is adopted as a core structure, the benzo-seven-membered ring can well occupy an S1 pocket of the blood coagulation factor XIIa due to the large size and space flexibility, the affinity of molecules and a target spot is remarkably improved, and therefore the inhibition activity, selectivity and in-vitro anticoagulation and anti-inflammatory activity of the blood coagulation factor XIIa are improved, and the compound has good application prospects on the basis of avoiding or reducing the bleeding risk. The pharmaceutical composition is used for preventing and treating thrombus inflammation diseases, such as sepsis and atherosclerosis.

A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.

Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.

To provide nucleic acid sequences, expression vectors (e.g., vector genomes) and plasmids, compositions and viral vectors in which the nucleic acid encodes Factor IX (e.g. human Factor IX).SOLUTION: A nucleic acid sequence encodes human Factor IX protein, where the nucleic acid has a reduced number of CpG di-nucleotides compared to a wild-type sequence encoding human Factor IX.SELECTED DRAWING: None

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and / or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and / or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.

The present application belongs to the technical field of blood product preparation, and particularly relates to a method for separating blood coagulation factor VIII and vWF factor from blood plasma. The method comprises the following steps in sequence: after cellulose is balanced, the cellulose is mixed with raw material blood plasma, filtered after stirring, and cellulose precipitate is obtained; after the cellulose precipitate is eluted, the cellulose precipitate is soaked in precipitate dissolving solution, and filtrate is obtained by filtering; the filtrate is subjected to three times of ion exchange chromatography, and factor VIII and / or vWF factor product is obtained. The technical scheme solves the technical problems of the prior art, such as complicated process steps for purifying and enriching human blood coagulation factor VIII and vWF from blood plasma cold precipitate, and unsatisfactory production efficiency and product quality. The cold precipitate protein solution prepared by the method can separate factor VIII, vWF factor and fibrinogen product at the same time through chromatography, improve the utilization rate of plasma protein, and has an ideal application prospect.

The invention relates to the field of natural product chemistry, sugar chemistry and biological medicine, and particularly provides glycosaminoglycan and / or a series of derivatives thereof as well as a preparation method and application of the glycosaminoglycan and / or the series of derivatives thereof, the glycosaminoglycan is extracted from starfish glabrata, and the preparation method comprises the following steps: extracting by adopting a papain combined alkaline hydrolysis method; the invention discloses an ALHX-2M series derivative and application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases, and the ALHX-2M series derivative is obtained by performing separation and purification through ion exchange column chromatography and molecular exclusion column chromatography to obtain ALHX-2M, and further performing deacetylation, deamination and depolymerization treatment and gel column chromatography separation and purification on the ALHX-2M series derivative and the application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases. The glycosaminoglycan and the derivative thereof take an endogenous blood coagulation factor X enzyme complex (FXase) as an action target, the anticoagulation activity and the antithrombotic activity of the glycosaminoglycan and the derivative thereof are superior to those of low-molecular-weight heparin, the bleeding risk under the equivalent antithrombotic dosage is remarkably reduced, and the glycosaminoglycan and the derivative thereof can be used for medicines or functional foods for preventing and treating thrombotic cardiovascular and cerebrovascular diseases.

Provided herein, are compositions based on retroviruses (e.g., lentiviruses) comprising one or more nucleic acid molecules encoding retroviral Pol polyprotein components and a nucleic acid molecule comprising one or more transgene sequences flanked by long terminal repeat sequences, for delivery of the one or more transgenes to a target cell ex vivo or in vivo. The compositions are useful for delivering to a target cell (e.g., hematopoietic stem cells (HSCs), liver cells, ocular cells, muscle cells, epithelial cells, T cells, etc.) and / or stably expressing any transgene (e.g., beta-globin, Factor VIII, RP GTPase regulator (RPGR), dystrophin, cystic fibrosis transmembrane conductance regulator (CFTR), a chimeric antigen receptor, etc.) with a biological effect to treat and / or ameliorate the symptoms associated with any disorder related to gene expression (e.g., sickle cell disease, beta-thalassemia, haemophilia B, retinitis pigmentosa, Duchenne muscular dystrophy, cystic fibrosis, cancer, etc.).

The invention discloses a sea snake tail glycosaminoglycan as well as a derivative, a pharmaceutically acceptable salt, a preparation method and an application of the sea snake tail glycosaminoglycan. The sea snake tail glycosaminoglycan has a structure as shown in a formula (I), is prepared by extracting, separating and purifying the sea snake tail, and is further subjected to deacetylation, carboxyl reduction, peroxidation depolymerization, deacylation and deamination depolymerization and gel column chromatography to obtain various derivatives of the sea snake tail glycosaminoglycan. The glycosaminoglycan compound and the derivative thereof show remarkable anticoagulation and antithrombotic activity, are low in bleeding risk, mainly act on an endogenous blood coagulation factor X enzyme complex (FXase) and a heparin cofactor II (HCII), and can provide a new thought for preparing medicines or functional foods for treating and / or preventing thrombotic diseases.

The preparation method comprises the following steps: adding chitosan and bletilla striata polysaccharide into an acidic aqueous solution, stirring and dissolving to obtain a first solution, and adding alkali and antibacterial and anti-inflammatory particles into the first solution to obtain a first suspension; adding chitosan into an acidic aqueous solution, stirring and dissolving to obtain a second solution, and adding alkali into the second solution to obtain a second suspension; and sequentially adding the second suspension liquid, the nylon film and the first suspension liquid into a mold, and freezing the mold, so that the chitosan random layer formed by the second suspension liquid has a disordered structure, and the chitosan orientation layer formed by the first suspension liquid has an orientation structure. The hemostatic sponge prepared by the invention can quickly absorb blood at a wound part, and chitosan and bletilla striata polysaccharide synergistically activate blood coagulation factors to accelerate blood coagulation; meanwhile, tissue fluid, serum and other liquids are adsorbed to the upper layer by the random layer, red blood cells and the like are blocked in the lower layer by the nylon film, blood clot formation is promoted, and then the hemostasis efficiency is remarkably improved.

The invention provides a preparation method of a hydrogel microneedle dressing, which comprises the following steps: fully dissolving chitosan in a glacial acetic acid aqueous solution to obtain a chitosan solution; the preparation method comprises the following steps: respectively dissolving polyvinyl alcohol and polyvinylpyrrolidone in water to obtain a polyvinyl alcohol solution and a polyvinylpyrrolidone solution; mixing the obtained solutions to obtain a hydrogel prepolymerization solution; and injecting the hydrogel pre-polymerized liquid into a hole of a microneedle mold by repeatedly vacuumizing, standing to form gel, drying and demolding to obtain the hydrogel microneedle dressing. The hydrogel microneedle dressing prepared in the invention has the advantages of excellent mechanical properties, good hemostatic performance, bacteriostasis, anti-inflammation and liquid absorption capability; when in use, the hemostatic gel can rapidly swell after penetrating through the cuticle, absorb tissue exudate and rapidly form a blood coagulation barrier, the hemostatic efficiency is enhanced through dual mechanisms of positive charge adsorption and blood coagulation factor activation, inflammatory factors are continuously inhibited, and rapid hemostasis, antibiosis and anti-inflammation are realized.

Protein molecules comprising a variant factor Xa (fXa) or fragments thereof and the use of such protein molecules in the treatment of disease, such as a thrombin-mediated condition, methods of detecting the presence of fVa and a kit comprising the protein molecules of the invention.

The application relates to urine protein markers for differential diagnosis of acute myocarditis and acute myocardial infarction and application thereof, the protein markers including one or more of tumor necrosis factor receptor superfamily member 1A, blood coagulation factor IX and peroxidase 3. The three markers have strong differential diagnosis ability to patients with acute myocarditis and acute myocardial infarction, thereby providing a new noninvasive differential diagnosis method for the two diseases.

Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The invention belongs to the technical field of biology, and particularly relates to a deep sea anticoagulant peptide, a composition thereof, a preparation method and application of the deep sea anticoagulant peptide in food, health food and medicine. The deep sea anticoagulant peptide is obtained by taking deep sea hippocampal clam as a raw material, crushing, carrying out enzymolysis by adopting pepsin, and carrying out freeze drying. The average molecular weight of the obtained peptide is less than 2000Da, and the peptide has excellent blood coagulation factor XIa inhibitory activity and antithrombotic effect. The deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE is obtained through separation and purification by Sephadex G15 gel chromatography and Sepax GP-C18 reversed-phase chromatography and by utilizing an AlphaFold3-assisted virtual screening technology, and the IC50 of the deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE is 194.9 mu M. The deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE can be used for preparing the deep sea blood coagulation factor XIa inhibitory peptide IFERIAAE. An in-vitro anticoagulation experiment result shows that the peptide can remarkably prolong activated partial thromboplastin time (APTT) and has a remarkable anticoagulation effect. The anticoagulant peptide provided by the invention is derived from deep sea shellfish, is novel in sequence and low in molecular weight, can be used as a template molecule for further modification for research and development of peptide anticoagulant or antithrombotic drugs, and has a wide application prospect.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to an improved method for determining the amount of FVIII inhibitors in a patient sample, comprising the provision of a patient plasma sample, a normal pool plasma samples, and a control plasma sample which is FVIII / VWF deficient, inactivating all clotting factors present in the samples, addition of recombinant FVIII (rFVIII) to the control plasma sample, combination of the patient plasma sample with the control plasma sample with rFVIII to obtain a test mixture, and of the normal plasma pool sample with the control plasma sample with rFVIII to obtain a control mixture, incubation of the test mixture and the control mixture for less than 30 minutes, and analyzing the mixtures for residual rFVIII activity in the absence of VWF.

The present invention relates to the field of hemodialysis technology, and more specifically, to a glacial acetic acid dialysis concentrate and a preparation method thereof. The present invention provides an anti-coagulation factor VIII antibody, and applies the antibody to the preparation of a glacial acetic acid dialysis concentrate. Analysis of the results shows that the introduction of the anti-coagulation factor VIII antibody significantly improves the blood coagulation phenomenon of the glacial acetic acid dialysis concentrate, and reduces the risk of increased coagulation and thrombosis in commercial glacial acetic acid dialysis fluid. At the same time, the stability of the dialysis fluid can be effectively improved, and the dialysis fluid can be suitable for long-term storage without deterioration. The application prospects of glacial acetic acid dialysis fluid are significantly improved, especially for hemodialysis of patients with acute and chronic renal failure and patients with drug poisoning, which will bring many advantages.

The present disclosure provides double-stranded ribonucleic acids and modifications and uses thereof for reducing expression of coagulation factor XI. Cell experimental results show that the oligonucleotide duplexes of the present disclosure can significantly inhibit the expression of FXI gene, and can be used for developing anticoagulant drugs.

This treatment offers comparable efficacy to existing therapies but with reduced bleeding risk, and provides a safer treatment that can reduce thromboembolic complications of AF, such as stroke, systemic embolism, cognitive decline, and mortality. [Solution] The present invention provides a monoclonal antibody that binds to human coagulation factor XI and XIa (activated factor XI) and its antigen-binding fragment, as well as a pharmaceutical composition containing the same, and a treatment method comprising the step of administering the same.

The invention relates to an in vitro method for measuring fibrin clot degradation based on a fibrin clot lysis curve over time in a blood or plasma sample previously obtained from a patient suspected of having a deficiency in at least one coagulation factor. This method includes determining a baseline fibrin clot level at time t1 and determining a degraded fibrin clot level at a subsequent time t2. The method may include an additional step of classifying the tested sample into a group reflecting a fibrin clot lysis profile. The invention also relates to a method for monitoring therapeutic treatment administered to a patient suspected of having, or who has, a deficiency in at least one coagulation factor. This method may further include a step of adjusting the patient's therapeutic treatment based on the classification obtained.The invention relates to enclosing the use of tranexamic acid (TXA) or a composition comprising it for use in a therapeutic treatment, said use comprising the implementation of a method according to the invention, and means for the implementation of the invention.